X4 Pharmaceuticals Inc Q2 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ellen Sands - Stifel, Nicolaus & Company - Analyst : Hi, this is Ellen Sands on for Steve. Thanks for taking the question. So, my first question, is there any scenario whereby you decided dose escalate beyond 600 milligrams in the Waldenstrom's trial? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JULY 30, 2020 / 12:30PM, XFOR.OQ - Q2 2020 X4 Pharmaceuticals Inc Earnings Call

Question: Ellen Sands - Stifel, Nicolaus & Company - Analyst : Okay, makes sense. And then, maybe just two more for me, so can you remind us if you predefined, give a number of representative genotypes that you want to specifically enroll in the Phase 1b for SCN or is it all comers? I know you're looking at genetic panel for the patients.

Question: Ellen Sands - Stifel, Nicolaus & Company - Analyst : Okay, great. And then last one, are there any updates around potential collaborative partners for mavorixafor in solid tumors?

Question: Ben Shim - Canaccord Genuity LLC - Analyst : Good morning. It's Ben Shim for Arlinda. Thanks for taking my questions. Paula, just a couple general ones, can you give us an idea of what the scope of the Phase 1b Waldenstrom's data will be, what will be provided and maybe nail down a little bit more specific timing for that? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JULY 30, 2020 / 12:30PM, XFOR.OQ - Q2 2020 X4 Pharmaceuticals Inc Earnings Call

Question: Ben Shim - Canaccord Genuity LLC - Analyst : Okay, great. Just a second quite a general question. As we get closer to getting hopefully a COVID-19 vaccine as early as this fourth quarter, my question to you is how directly relevant do you think this vaccine will be to your patient populations in each of the three indications you're studying directly or indirectly and is this recalibrating maybe your expectations for enrollment and potential data readouts? Thanks.

Question: Leland Gershell - Oppenheimer & Co. Inc. - Analyst : Hey, good morning guys. Thank you for the update, thanks for taking the questions. Actually, I wanted to ask on the earlier pipeline behind mAb and 002, 003, I just want to check in if we'll be hearing a news flow on those compound, the programs for those later this year or perhaps in '21? Thanks.

Question: Leland Gershell - Oppenheimer & Co. Inc. - Analyst : The indication that you have listed, right, I think it was [GBM 402]?

Question: Joel Beatty - Citi - Analyst : Hi, thanks for taking the questions. For the Waldenstrom's data coming out later this year, could you describe what would be next for the program if the data is successful?

Question: Joel Beatty - Citi - Analyst : Great, that's helpful. And then with that Phase 2/3 trial be in the current cash runway guidance?

Question: Joel Beatty - Citi - Analyst : Yes, the cash runway to early 2022?

Question: Joel Beatty - Citi - Analyst : Okay, sounds great. Thank you.

Question: Swayampakula Ramakanth - H.C. Wainwright - Analyst : Thank you. Good morning, Paul and Adam. Most of my questions had been answered. However, I just want to check on a couple of things. Any update you can provide on enrollment stats in your clinical studies, given the current environment? And the second question is on the collaboration with Invitae for generating the genetic test or the diagnostic test that you want to generate.

Question: Swayampakula Ramakanth - H.C. Wainwright - Analyst : Thank you. Thank you both.

Question: Laura Christianson - Cowen - Analyst : Thanks. Good morning. Thanks for taking my question. Just following up on the earlier one about the Waldenstrom's trial and expectations for the readout, I just was wondering if you can provide any more clarity about maybe the number of patients that will be at the 600-milligram dose. And how much -- how robust the IgM reduction data might be just given that we don't know exactly when the patient is enrolled and cut-off for when you'll be presenting the data?

Question: Zegbeh Jallah - ROTH Capital Partners - Analyst : Good morning. I feel like a lot of the questions had been asked and I think the update was in line with (inaudible) patients, so just a quick question regarding thoughts on partnership now that you've added some WHIM data and you're going to have Waldenstrom's coming up soon. I know they're rare diseases but in aggregate it's a large opportunity, so just thinking in terms of partnerships what were your thoughts there? And then, you did state that the efforts from Invitae hasn't fully materialized yet but I was just wondering if you had any learnings that you could communicate as you're going after these patient's awareness efforts and things like that.

Question: Mayank Mamtani - B. Riley FBR - Analyst : Good morning. Thanks for taking my question and impressive [Walden] reduction data indeed at EHA and congrats to Renato also for the promotion. Could you just remind us about the status of the manuscript for this data? And I know you talked a lot about Invitae, just any near term learnings from that could also help the SCN Phase 1b study enrollment that you could comment on that.

Question: Mayank Mamtani - B. Riley FBR - Analyst : Okay, great and then on the WHIM Phase 3 study, can you comment on the proportion of sites, again U.S., ex-U.S. and even within U.S., how many might be in the south. Any color you could give?

Question: Mayank Mamtani - B. Riley FBR - Analyst : Okay, great. And just final question on Waldenstrom's, can you comment on like how many or what proportion of patients are in the part 2 that you just talked about, Paula?